INTS (Intensity Therapeutics, Inc. Common stock) Stock Analysis - News
Intensity Therapeutics, Inc. Common stock (INTS) is a publicly traded Healthcare sector company. As of May 21, 2026, INTS trades at $4.62 with a market cap of $12.38M and a P/E ratio of -0.54. INTS moved +0.87% today. Year to date, INTS is -53.23%; over the trailing twelve months it is -55.35%. Its 52-week range spans $4.50 to $100.00. Analyst consensus is buy with an average price target of $25.00. Rallies surfaces INTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in INTS news today?
Intensity Therapeutics Wins 2026 Cancer Treatment Technology Innovator Award: Intensity Therapeutics received the Cancer Treatment Technology Innovator of the Year 2026 – USA award for its proprietary INT230-6 non-covalent intratumoral drug-conjugation technology. The late-stage clinical therapy has demonstrated encouraging outcomes in advanced sarcoma and breast cancer patients with no remaining treatment options.
Intensity Therapeutics Wins 2026 Cancer Treatment Technology Innovator Award: Intensity Therapeutics received the Cancer Treatment Technology Innovator of the Year 2026 – USA award for its proprietary INT230-6 non-covalent intratumoral drug-conjugation technology. The late-stage clinical therapy has demonstrated encouraging outcomes in advanced sarcoma and breast cancer patients with no remaining treatment options.
Does Rallies summarize INTS news?
Yes. Rallies summarizes INTS news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is INTS research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INTS. It does not provide personalized investment advice.
